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Background: Randomized trials have consistently shown that reducing low-density lipoprotein cholesterol (LDL-C) reduces the risk of major 
cardiovascular events (MCE), whereas trials of therapies that increase high-density lipoprotein cholesterol (HDL-C) have not. We sought to estimate 
the potential clinical benefit of adding an HDL-C raising therapy to treatment with a statin.
Methods: We conducted a meta-regression analysis of statin trials to estimate the effect of raising HDL-C on the risk of MCE after controlling 
for the effect of reducing LDL-C, and to develop a regression equation to predict the expected clinical benefit from the combined effect of raising 
HDL-C and reducing LDL-C. We then conducted a systematic review and meta-analysis of trials evaluating the addition of an HDL-C raising therapy to 
treatment with a statin. Finally, we compared the expected clinical benefit predicted by the meta-regression equation with the observed results from 
the meta-analysis of HDL-C raising therapies.
Results: In a meta-regression analysis of 26 statin trials including 169,138 participants, we found that the risk of MCE was reduced by 19% (RR: 
0.81, 95%CI: 0.71-0.93) per mmol/L reduction in LDL-C independent of the change in HDL-C. By contrast, we found no reduction in the risk of MCE 
per mmol/L increase in HDL-C (RR: 1.11, 95%CI: 0.27-4.66), after controlling for the effect of lowering LDL-C. In a meta-analysis of 5 trials including 
26,799 participants, the addition of a therapy to raise HDL-C to treatment with a statin did not reduce the risk of MCE (RR: 1.05, 95%CI: 0.91-
1.22), despite a weighted mean increase in HDL-C of 24.5 mg/dl (0.63 mmol/L) and a weighted mean additional reduction in LDL-C of 16.0 mg/
dl (0.41 mmol/L). The expected clinical benefit from the combined changes in HDL-C and LDL-C predicted by the meta-regression equation agreed 
closely with the overall summary estimate of effect of the meta-analysis and the observed results from each of the HDL-C trials. These results were 
unchanged after excluding the ILLUMINATE trial.
Conclusion: The available evidence suggests that adding an HDL-C raising therapy to treatment with a statin is unlikely to produce a substantial 
clinical benefit.
